# The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation

Study · id `cardio:ct-nct04217135` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04217135](<https://clinicaltrials.gov/study/NCT04217135>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04217135

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT04217135. Randomized; no masking; primary purpose diagnostic. Start 2017-01-01 (actual); primary completion 2022-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT04217135, source copy `cardio:ctgov-nct04217135-2022-01-06`, retrieved 2026-10-26)
- Started: 2017-01-01 (actual) (ClinicalTrials.gov record NCT04217135, source copy `cardio:ctgov-nct04217135-2022-01-06`, retrieved 2026-10-26)
- Primary completion: 2022-07-31 (anticipated) (ClinicalTrials.gov record NCT04217135, source copy `cardio:ctgov-nct04217135-2022-01-06`, retrieved 2026-10-26)
- Completion: 2022-07-31 (anticipated) (ClinicalTrials.gov record NCT04217135, source copy `cardio:ctgov-nct04217135-2022-01-06`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT04217135, source copy `cardio:ctgov-nct04217135-2022-01-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04217135-2022-01-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
- Condition: Systolic Heart Failure Stage D (Disorder)
- Condition: Mitral Regurgitation
- Intervention (Drug): evidence-based medications vs. high-dose hydralazine + evidence-based medications
- Lead sponsor: Kaohsiung Veterans General Hospital.
- Lead sponsor class: OTHER
- Collaborator: E-DA Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as a collaborator: E-DA Hospital (`cardio:org-e-da-hospital`)

## Provenance

Content hash: 4eee860b0c5f63a5cb2df0c5337719aaf5d6484f0b9eff9d40cb0c0f2eb7d963
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
